C4 Therapeutics Inc. has outlined a multi-year strategy focused on advancing its targeted protein degradation platform across drug discovery, clinical development, and commercialization. Key elements of the plan include rapidly developing cemsidomide as a potential foundational therapy for multiple myeloma, with the initiation of the Phase 2 MOMENTUM trial in the first quarter of 2026 and a Phase 1b combination trial with elranatamab set to begin in the second quarter of 2026. The company has selected a recommended Phase 2 dose of 100 µg for cemsidomide. Additionally, C4 Therapeutics is implementing a new discovery strategy aimed at developing degrader medicines for five novel targets across inflammation, neuro-inflammation, and neuro-degenerative disease pathways. The company reports a cash runway extending through the end of 2028, intended to support progress through key value inflection points in its portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625215-en) on January 14, 2026, and is solely responsible for the information contained therein.